CN103172687B - 一种奈拉滨结晶化合物及其制备方法 - Google Patents
一种奈拉滨结晶化合物及其制备方法 Download PDFInfo
- Publication number
- CN103172687B CN103172687B CN201310103874.5A CN201310103874A CN103172687B CN 103172687 B CN103172687 B CN 103172687B CN 201310103874 A CN201310103874 A CN 201310103874A CN 103172687 B CN103172687 B CN 103172687B
- Authority
- CN
- China
- Prior art keywords
- nelarabine
- preparation
- crystalline compound
- nelzarabine
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 title claims abstract description 145
- 229960000801 nelarabine Drugs 0.000 title claims abstract description 145
- 150000001875 compounds Chemical class 0.000 title claims abstract description 118
- 238000002360 preparation method Methods 0.000 title claims abstract description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 150
- 239000012043 crude product Substances 0.000 claims abstract description 21
- 239000012065 filter cake Substances 0.000 claims abstract description 21
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 21
- 238000001816 cooling Methods 0.000 claims abstract description 19
- 238000010992 reflux Methods 0.000 claims abstract description 18
- 238000000967 suction filtration Methods 0.000 claims abstract description 16
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 238000005406 washing Methods 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 40
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
- 238000003756 stirring Methods 0.000 claims description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
- 238000002425 crystallisation Methods 0.000 claims description 24
- 230000008025 crystallization Effects 0.000 claims description 24
- 239000002994 raw material Substances 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 23
- 239000000706 filtrate Substances 0.000 claims description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- 230000015572 biosynthetic process Effects 0.000 claims description 18
- 239000007789 gas Substances 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 238000003786 synthesis reaction Methods 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 238000010189 synthetic method Methods 0.000 claims description 8
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 238000010792 warming Methods 0.000 claims description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 5
- 238000004440 column chromatography Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 230000000630 rising effect Effects 0.000 claims description 5
- 239000011550 stock solution Substances 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 2
- 238000005352 clarification Methods 0.000 claims description 2
- 238000009413 insulation Methods 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims description 2
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 25
- 239000013078 crystal Substances 0.000 abstract description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 229940079593 drug Drugs 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- -1 nucleoside compound Chemical class 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000005252 bulbus oculi Anatomy 0.000 description 9
- 239000000356 contaminant Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 241001249696 Senna alexandrina Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- NYHBQMYGNKIUIF-UHFFFAOYSA-N 2-amino-9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 238000002447 crystallographic data Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- HMFHBZSHGGEWLO-HWQSCIPKSA-N L-arabinofuranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-HWQSCIPKSA-N 0.000 description 1
- MQLRJOOIZYEGFJ-SEGPTPNXSA-N Nc1nc(Cl)c2nc[n]([C@@H]([C@H]([C@@H]3OCc4ccccc4)OCc4ccccc4)O[C@@H]3[IH]OCc3ccccc3)c2n1 Chemical compound Nc1nc(Cl)c2nc[n]([C@@H]([C@H]([C@@H]3OCc4ccccc4)OCc4ccccc4)O[C@@H]3[IH]OCc3ccccc3)c2n1 MQLRJOOIZYEGFJ-SEGPTPNXSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 150000002243 furanoses Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
药物 | 25℃溶解度 |
本发明实施例1 | 18.8mg/ml |
本发明实施例2 | 18.9mg/ml |
本发明实施例3 | 18.3mg/ml |
本发明实施例4 | 18.7mg/ml |
本发明实施例5 | 18.5mg/ml |
本发明实施例6 | 19.1mg/ml |
本发明实施例7 | 19.2mg/ml |
本发明实施例8 | 19.1mg/ml |
对照药物1 | 8.7mg/ml |
对照药物2 | 8.5mg/ml |
对照药物3 | 8.9mg/ml |
批号 | α-异构体(%) | 最大杂质(%) | 有关物质(%) |
20121201 | 0.00 | 0.08 | 0.09 |
20121202 | 0.02 | 0.10 | 0.12 |
20121203 | 0.00 | 0.07 | 0.08 |
批号 | α-异构体(%) | 最大杂质(%) | 有关物质(%) |
20121204 | 0.05 | 0.13 | 0.14 |
20121205 | 0.07 | 0.15 | 0.17 |
20121206 | 0.05 | 0.12 | 0.13 |
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310103874.5A CN103172687B (zh) | 2013-03-28 | 2013-03-28 | 一种奈拉滨结晶化合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310103874.5A CN103172687B (zh) | 2013-03-28 | 2013-03-28 | 一种奈拉滨结晶化合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103172687A CN103172687A (zh) | 2013-06-26 |
CN103172687B true CN103172687B (zh) | 2015-07-08 |
Family
ID=48632937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310103874.5A Active CN103172687B (zh) | 2013-03-28 | 2013-03-28 | 一种奈拉滨结晶化合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103172687B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104193801A (zh) * | 2014-08-12 | 2014-12-10 | 苏州维泰生物技术有限公司 | 一种鸟嘌呤肽核酸单体及其合成方法 |
CN106317150B (zh) * | 2016-08-22 | 2019-02-15 | 山东罗欣药业集团股份有限公司 | 一种抗肿瘤药物的晶型化合物及其制备方法 |
CN106397517B (zh) * | 2016-08-22 | 2019-02-15 | 山东罗欣药业集团股份有限公司 | 一种治疗白血病的化合物及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101092441A (zh) * | 2007-07-17 | 2007-12-26 | 北京本草天源药物研究院 | 一种奈拉滨的合成方法 |
CN101402662A (zh) * | 2008-11-07 | 2009-04-08 | 江苏奥赛康药业有限公司 | 一种奈拉滨的制备方法 |
CN101768197A (zh) * | 2008-12-29 | 2010-07-07 | 北京德众万全药物技术开发有限公司 | 一种奈拉滨的制备方法 |
US20110033419A1 (en) * | 2009-08-07 | 2011-02-10 | University Of Maryland | Methods and Compositions for Treating Cancer |
-
2013
- 2013-03-28 CN CN201310103874.5A patent/CN103172687B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101092441A (zh) * | 2007-07-17 | 2007-12-26 | 北京本草天源药物研究院 | 一种奈拉滨的合成方法 |
CN101348511A (zh) * | 2007-07-17 | 2009-01-21 | 江苏正大天晴药业股份有限公司 | 奈拉滨的合成及精制 |
CN101402662A (zh) * | 2008-11-07 | 2009-04-08 | 江苏奥赛康药业有限公司 | 一种奈拉滨的制备方法 |
CN101768197A (zh) * | 2008-12-29 | 2010-07-07 | 北京德众万全药物技术开发有限公司 | 一种奈拉滨的制备方法 |
US20110033419A1 (en) * | 2009-08-07 | 2011-02-10 | University Of Maryland | Methods and Compositions for Treating Cancer |
Non-Patent Citations (1)
Title |
---|
李叶青,等.氟达拉宾的合成.《江苏化工》.2005,第33卷121-123. * |
Also Published As
Publication number | Publication date |
---|---|
CN103172687A (zh) | 2013-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102432526B1 (ko) | 디시클로플라틴의 제조방법 | |
CN103172687B (zh) | 一种奈拉滨结晶化合物及其制备方法 | |
CN108586355A (zh) | 一种奥拉帕尼的精制方法 | |
CN101475600A (zh) | 一种合成抗肿瘤药物卡铂的新方法 | |
CN103319548B (zh) | 一种蔗糖-6-乙酸酯的提纯方法 | |
CN108276414A (zh) | 一种枸橼酸托法替尼的制备方法 | |
CN111574454A (zh) | 咪唑离子液体功能化的杯四芳烃固定相的制备及其应用 | |
CN113173953B (zh) | 用于制备抗肿瘤药物的高纯洛铂三水合物的提纯方法 | |
EP3118207A1 (en) | Inclusion compound of 3',5'-cyclicdiadenylic acid, and method for producing same | |
JP6974788B2 (ja) | イミダゾピロロキノリン塩及びその製造方法、並びに、医薬品、化粧品及び食品 | |
WO2021129783A1 (zh) | 去亚甲基小檗碱的制备方法及其应用 | |
CN113816864B (zh) | 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法 | |
CN109251196A (zh) | 氨基苯并[d]氮杂*基喹唑啉类化合物及其制备方法和应用 | |
CN110028457B (zh) | 一种同位素标记的磺胺溴二甲嘧啶及其合成方法 | |
CN106946959B (zh) | 合成5,6,4'-三羟基黄酮-7-0-d-葡萄糖醛酸有关物质及其制备方法和应用 | |
CN100582115C (zh) | 一种合成抗肿瘤药物卡铂的方法 | |
CN104177293A (zh) | 5-氨基-7-三氟甲基喹啉及5-三氟甲基-7-氨基喹啉的合成方法 | |
CN111943933B (zh) | 一种来那替尼杂质d的制备方法 | |
CN110229170B (zh) | 一种5-氮杂Marangucycline B的制备方法 | |
CN104098523B (zh) | 1-异丁酰基-3-苯基-1,4-二氢-1,2,4,5-四嗪及制备和应用 | |
CN113336754B (zh) | 一种荧光探针及其制备方法 | |
CN112898277B (zh) | 一种阿法替尼中间体的制备方法 | |
CN108309984A (zh) | 丙酰氨基喹唑啉类化合物在制备治疗宫颈癌药物中的应用 | |
CN114716391B (zh) | 一种醋甲唑胺杂质及其制备方法和应用 | |
CN113135931B (zh) | 一种细胞松弛素类化合物flavipesine A的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG LUOXIN PHARMACY GROUP CO., LTD. Free format text: FORMER OWNER: SHANDONG LUOXIN PHARMACY STOCK CO., LTD. Effective date: 20150608 Owner name: SHANDONG YUXIN PHARMACEUTICAL CO., LTD. SHANDONG H Effective date: 20150608 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhu Yuqing Inventor after: Li Mingjie Inventor after: Han Fengsheng Inventor after: Li Zhibin Inventor after: Wang Xingyu Inventor before: Li Mingjie Inventor before: Han Fengsheng Inventor before: Li Zhibin Inventor before: Wang Xingyu |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LI MINGJIE HAN FENGSHENG LI ZHIBIN WANG XINGYU TO: ZHU YUQING LI MINGJIE HAN FENGSHENG LI ZHIBIN WANG XINGYU |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150608 Address after: Seven of 276017 Shandong province Linyi city Luozhuang District Applicant after: Shandong Luo Xin Pharmaceutical Group Plc Applicant after: Shandong Yu Xin pharmaceutcal corporation, Ltd Applicant after: SHANDONG HENGXIN PHARMACEUTICAL CO., LTD. Address before: Seven of 276017 Shandong province Linyi city Luozhuang District Applicant before: SHANDONG LUOXIN PHARMACY STOCK Co., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 276017 18 Luo Qi Road, Luozhuang District, Linyi, Shandong Co-patentee after: Shandong Yu Xin pharmaceutcal corporation, Ltd Patentee after: Shandong Luo Xin Pharmaceutical Group Plc Co-patentee after: Shandong Luoxin Pharmaceutical Group Hengxin Pharmacy Co., Ltd. Address before: 276017 Luoqi Road, Luozhuang District, Linyi City, Shandong Province Co-patentee before: Shandong Yu Xin pharmaceutcal corporation, Ltd Patentee before: Shandong Luo Xin Pharmaceutical Group Plc Co-patentee before: SHANDONG HENGXIN PHARMACEUTICAL CO., LTD. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210120 Address after: No.9 Tengfei Road, Yishui County, Linyi City, Shandong Province Patentee after: SHANDONG LUOXIN LEKANG PHARMACEUTICAL Co.,Ltd. Patentee after: SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK Co.,Ltd. Patentee after: SHANDONG YUXIN PHARMACEUTICAL Co.,Ltd. Patentee after: SHANDONG LUOXIN PHARMACEUTICAL GROUP HENGXIN PHARMACEUTICAL Co.,Ltd. Address before: 276017 18 Luo Qi Road, Luozhuang District, Linyi, Shandong Patentee before: SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK Co.,Ltd. Patentee before: SHANDONG YUXIN PHARMACEUTICAL Co.,Ltd. Patentee before: SHANDONG LUOXIN PHARMACEUTICAL GROUP HENGXIN PHARMACEUTICAL Co.,Ltd. |